The US' happiest shift workers sell weed and e-cigs — see where your industry ranks
America's most cheerful hourly employees aren't sitting behind a computer, it seems — they're at the counter selling vapes, weed and smokes, according to a new report from workplace management platform Deputy.
Over 1.51 million end-of-shift survey responses paint a less-than-ideal picture of the state of the union for wage workers.
Advertisement
The happiest hourly employees in the US are selling vapes, weed and smokes, according to a new report from workplace management platform Deputy.
REUTERS
While the Net Happiness Score — the report's metric for general workplace wellbeing — clocked in fairly high at 71.86%, it still took a tumble from 73% in 2024.
The happiest industry sector turned out to be e-cigarette and marijuana stores, with 91.87% of employees saying they feel 'good' or 'amazing' about their jobs.
Advertisement
They're closely followed by caterers, baristas, dentists and those who work in gyms, firearms stores and sit-down restaurants.
Meanwhile, the unhappiest industry sector title went — surprisingly — to pharmacies, which only landed a 13.94% rating.
Next were people who work in postal services, animal health, doctors' offices and other types of healthcare workers.
Some of the unhappiest industry sectors were in healthcare.
SneakyPeakPoints/peopleimages.com – stock.adobe.com
Advertisement
It's an upset to the status quo that proves once again that money can't buy happiness.
The report notes that the findings reflect 'the ongoing strain on healthcare workers, who continue to shoulder high emotional and physical workloads in a post-pandemic environment marked by staffing shortages, unpredictable hours and regulatory pressure.'
The results also suggest that 'improvements in flexibility, wage transparency and shift consistency may be helping' employers to 'boost morale' in spite of 'the well-documented
challenges of retail — such as long hours and customer-facing stress.'
Advertisement
All of which suggests that workplace camaraderie, clear goals and expectations and a sense of purpose can ultimately matter more when it comes to satisfaction than pay or prestige.
Notably, breaking the scores down by state reveals stark disparities — a gulf in America, if you will.
South Carolina, Virginia and Utah are performing well above the national satisfaction trend, thanks in part to strong investments in scheduling flexibility and supportive workplace cultures.
Conversely, North Dakota, New Mexico and Vermont scored much lower, due to economic pressure, understaffing and frustrations of feeling unheard and burnt out.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Novo Nordisk shares dip further as Wegovy gains nearly erased
By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago. The fall on Friday means the Danish firm has dropped out of the top 10 constituents of the Europe-wide STOXX 600 index. Share price declines across the sector were prompted by U.S. President Donald Trump, who sent letters on Thursday to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23% on the day. Novo became Europe's most valuable listed firm after launching Wegovy in June 2021, worth some $650 billion in the middle of last year. But its shares have lost more than two-thirds since on concerns the drugmaker is losing ground in the obesity drug race. Its market cap is now $214.5 billion. "The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices," Novo said in an emailed statement. Novo's shares were around 2% lower at 1453 GMT, bringing this week's losses to around 30% - the stock's worst week ever. The European healthcare index was down around 1% to its lowest since April. "Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade," said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. "This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump," Hansen said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
CVS second-quarter profit beats estimates, helped by medical cost oversight
By Amina Niasse NEW YORK (Reuters) -CVS Health beat Wall Street estimates for second-quarter profit on Thursday, as tight oversight of higher medical costs led to improved performance for its Aetna health insurance business. The company also flagged improved performance in its national pharmacy chain and pharmacy benefit management businesses. CVS reported an adjusted quarterly profit of $1.81 per share, above the average analyst estimate of $1.46 per share, according to LSEG data. For full-year 2025, the insurer raised its profit outlook to $6.30 to $6.40 per share, compared with an average analyst estimate of $6.12 as compiled by LSEG. It attributed the raised forecast to its second-quarter performance. CVS previously had expected full-year earnings per share of $6.00 to $6.20. CVS Health's Aetna insurance business reported a medical loss ratio, or the percentage of premiums spent on medical services, of about 89.9% in the second quarter. Analysts expected a ratio of 91.16%, according to LSEG estimates. It was the third quarter in a row that CVS beat earnings targets as the company works on a turnaround after having missed financial targets repeatedly last year. Those problems had stemmed from an unexpected sharp rise in medical costs in its Medicare Advantage plans for people aged 65 and older or with disabilities, and struggles with its pharmacies. "Nothing is a surprise to us this quarter," said CEO David Joyner in an interview with Reuters. Joyner, who joined the company last October, said the Aetna business experienced higher costs in its Medicare Advantage plans sold through groups such as employers or retiree organizations, but those costs were accurately anticipated. Aetna aims to reprice half of those plans for 2026, he added. CVS plans to close 250 brick-and-mortar pharmacies this year in an effort to cut costs, and the company is reducing its government-sponsored health insurance plans. Rivals including UnitedHealth, Elevance and Centene have detailed higher-than-expected medical costs for the second quarter due to a sicker patient profile and mismatched government payment rates, primarily in Medicaid plans for low-income people. Government payment pressure in Medicare Advantage plans has also squeezed insurer margins this year, with the Centers for Medicare and Medicaid Services changing its calculations of how to reimburse plans for their sickest members. Joyner said CVS's primary care unit for seniors, Oak Street Health, is impacted by these regulatory changes, but the changes are manageable. Revenue for CVS's health services segment, which houses its Caremark pharmacy benefit manager, rose 10.2%, due to a more favorable drug mix and plan renewals from existing clients, the company said. Revenue for the retail-pharmacy and drug-infusion business increased by 12.5% during the second quarter, which Joyner said was aided by increases in prescription volumes filled. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
5 days ago
- Yahoo
Wegovy maker Novo's profit warning triggers $70 billion share rout
By Jacob Gronholt-Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market. Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started. Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously. Its shares plunged nearly 30% before paring some losses to trade down over 20% by mid-afternoon. The shares are now down 44% this year. "The magnitude of the guidance cut is a shocker," Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than "compounded" copycats to Wegovy. Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. U.S. law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations. The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the U.S., both for Wegovy and Ozempic in the GLP-1 diabetes market. The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen. At its peak in June 2024, Novo was worth as much as $615 billion, but its shares have plunged on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market. "The stock has gone from being a market darling to one of its biggest letdowns," said Angelo Meda, portfolio manager and head of equities at Banor SIM in Milan, which has a small Novo stake. "The biggest concern is the illegal channel siphoning away market share - something that's hard to quantify. Rebuilding trust will take time." NEW CEO AN INSIDER Doustdar, an Iranian-born, Austrian national, who grew up in the United States, joined Novo in 1992 and will take on the new role on August 7. He currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. "We need to increase the sense of urgency and execute differently," Doustdar told investors and analysts on a call. "The fact that my announcement comes right after the guidance update, just makes the mandate ahead even more clear." Some analysts and investors had argued that Novo should select an American, or a person with extensive experience working in the United States as its next CEO. Novo has lost its first-mover advantage in the United States this year to U.S. rival Eli Lilly. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. In May, Novo said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22. "Unfortunately, our latest market research indicates that has not happened," Chief Financial Officer Karsten Munk Knudsen said on a call with analysts on Tuesday. One million or more U.S. patients are still using compounded GLP-1s, he said. Novo has stepped up its dialogue with the U.S. FDA to limit unlawful compounding of its drugs, the head of U.S. operations David Moore added on the call. "Compounding continues to be an issue that we have to address," Moore said. ($1 = 0.8672 euros) Sign in to access your portfolio
